In 1990, Nada et al 1 reported the first three patients who had an initial diagnosis of idiopathic pulmonary fibrosis (IPF) but later were correctly diagnosed as having pulmonary-renal vasculitis. Circulating perinuclear-antineutrophil cytoplasmic autoantibodies (P-ANCAs) were detected in two patients. These seminal cases underscored the importance of a high index of suspicion for systemic vasculitis in elderly patients and the need to consider vasculitis in the differential diagnosis of IPF. Since then, several small series described patients with pulmonary fibrosis (PF) associated with ANCA-positive vasculitis [e.g., microscopic polyangiitis (MPA) and rapidly progressive glomerulonephritis]. Further, PF has been observed in pathological series of ANCA-associated lung diseases. 2, 3 However, the possible link between PF, ANCA positivity, and vasculitis is poorly understood. During the past 6 years, five retrospective casecontrol studies were published [4] [5] [6] [7] [8] (Table 1 ). These studies indicate that PF is an underestimated manifestation of ANCA-associated vasculitis.
CLINICAL CHARACTERISTICS OF ANCA-ASSOCIATED LUNG FIBROSIS
Hervier et al 6 retrospectively investigated 12 patients with PF fulfilling the international consensus statement criteria for IPF 9 and associated with ANCA-positive vasculitis (fulfilling the Chapel Hill Classification criteria for vasculitis). 10 Common clinical characteristics (Table 1) . Microscopic polyangiitis (MPA) was diagnosed in 7/17 patients (41%) in the ANCApositive cohort and was never observed in 12 ANCAnegative patients. In six of seven patients, MPA developed after PF, with a mean delay of 53 months (range: 15 to 137 months) ( Table 1 ). The diagnosis of PF and MPA was concomitant in only one patient. Among seven patients with MPA, alveolar hemorrhage was noted in six. During follow-up, 10/17 patients in the ANCA-positive cohort died (three directly related to vasculitis). Tzelepis et al 8 reported 33 patients with MPA and (positive) ANCA. PF was present in 12 (36%) at presentation and developed in one additional patient while on therapy for MPA. All had renal involvement (necrotizing, segmental glomerulonephritis). Prognosis was worse among patients with PF (six deaths in the PF cohort compared with one death in the non-PF cohort, p ¼ 0.02). Nozu et al retrospectively reviewed 53 patients with PF who had been tested for ANCA. 5 Overall, circulating ANCAs were found in 19 (37%) [including MPO in 17 and proteinase 3 (PR3) in two]. Among patients with ANCA-positive PF, patients with MPA had higher ANCA titer than those without vasculitis. 5 It remains unclear, however, whether high ANCA titers can predict the development of vasculitis among patients with ANCA-positive PF.
Outcome Prognosis of ANCA-associated PF is generally poor. In the retrospective study by Nozu et al, survival was analyzed among 53 patients with IPF. 5 Among 19 patients with ANCA-positive PF, six (31%) died (1 to 90 months) and four (21%) were lost to follow-up. Among 34 patients in the ANCA-negative cohort, 15 died (44%) (1 to 58 months) and 12 (36%) were lost to follow-up. These mortality rates were not statistically different between cohorts. However, the low-titer (<50 EU) group showed better survival than the high-titer (>50 EU) group in ANCA-positive lung fibrosis. In this retrospective study, HRCT improved with corticosteroid/immunosuppressive therapy in 14/17 patients with ANCA-positive PF. 5 However, details of extent of improvement were not provided.
Foulon et al studied 17 patients with ANCAassociated PF. 7 During the course of follow-up, seven patients developed MPA. Six of 7 patients with MPA died (three as a direct result of vasculitis). 7 In addition, four of the 10 patients who did not develop MPA died during follow-up. Acute respiratory failure due to an exacerbation of PF occurred in two patients (BAL in one patient at the time of exacerbation showed no alveolar hemorrhage). Hervier et al retrospectively assessed 12 patients with PF and (positive) ANCA (all MPO-ANCA). 6 Two died during induction therapy (within 7 months) for vasculitis. Three died of progressive respiratory failure (range 37 to 67 months). In the remaining patients, the disease worsened in two and stabilized in five. Homma et al retrospectively reviewed 31 patients with PF and (positive) MPO-ANCA; [including 22 with connective tissue disease (CTD) and nine of unknown etiology]. 4 Overall, 13/31 (24%) died; causes of death included worsening PF (n ¼ 5), pneumonia (n ¼ 4), lung cancer (n ¼ 2), and gastrointestinal bleeding (n ¼ 2).
The prognosis of ANCA-associated PF is variable. Chronic forms of lung fibrosis with predominant honeycombing will likely not respond to immunosuppressive therapy (Fig. 1) , whereas subacute disease (particularly when ground-glass opacities (GGOs) are present on HRCT) may respond to immunosuppressive therapy 11 (Fig. 2) . The high mortality rate of ANCA-associated PF suggests that a search for ANCAs should be performed at diagnosis in every patient with PF because the presence of ANCAs will increase the risk of development of a vasculitis and promote specific monitoring, especially if the ANCAs are the MPO epitope.
Pathology
Reports on the histopathology of ANCA-associated PF are limited. Gaudin et al 2 reviewed the histological features of lung diseases in 27 patients (positive) for either cytoplasmic-ANCA (c-ANCA) (n ¼ 13) or MPO-ANCA (n ¼ 14). Predominant findings included capillaritis (17 patients, 63%), interstitial lesions (20 patients, 74%); necrotizing granulomatous inflammation (eight patients, 30%), fibrosis (13 patients, 48%), and chronic inflammation (12 patients, 44%). Homma et al retrospectively studied a cohort of 31 patients with PF who also had MPO-ANCAs. They identified eight patients with MPA. Of 15 biopsy and postmortem specimens available for histopathological study, 11 had background features of usual interstitial pneumonia (UIP) pattern. Five specimens showed vasculitis in pulmonary and/or bronchial arterioles. In addition, lymphoid hyperplasia and organizing pneumonia were often observed, similar to PF complicating CTD. Birnbaum et al 11 reported a patient with MPA who had subacute progression of interstitial lung disease and muscle involvement. Review of the lung biopsy specimen after the diagnosis of MPA revealed some findings suggestive of UIP, including foci of fibroblast proliferation, architectural remodeling with a honeycomb pattern, and a spatially and temporally heterogeneous pattern of fibrosis. In addition, there were histopathological features inconsistent with UIP such as foci of leukocytoclastic capillaritis, constrictive bronchiolitis, and a chronic hemorrhagic component, with regions of hemosiderinladen macrophages juxtaposed with fibroblast foci. French investigators reported three ANCA-positive patients who had undergone surgical lung biopsy; all cases showed UIP pattern with no vasculitis. 7 These discrepant results may be partly explained by the temporal and spacial heterogeneity of ANCA-associated PF. Eschun et al described histological findings (from surgical lung biopsy) in a patient with MPA who presented with PF.
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Wedge resection from the upper lobe revealed focal alveolar hemorrhage and nonspecific interstitial pneumonitis (NSIP) without significant fibrosis or honeycombing; however, specimens obtained from the lower lobe demonstrated honeycombing. HRCT may be a surrogate marker for fibrosis or alveolitis. UIP pattern is most common on computed tomography (CT), but CT features are heterogeneous [5] [6] [7] [8] (Table 1 ). In two small series, GGOs were noted in 100% 7 and 80% 5 of cases, respectively, in addition to the typical UIP features such as honeycombing and traction bronchoectasis (Table 1) .
Hypothetical View on the Pathogenesis of ANCA-Associated Lung Fibrosis
At least two mechanisms have been proposed for the development of ANCA-associated PF. The first hypothesis is that recurrent, subclinical alveolar hemorrhage might contribute to the development of PF in ANCAassociated vasculitis. This hypothesis is supported by some clinical findings. Subclinical pulmonary hemorrhage may have caused a restrictive lung defect in three siblings with a unique urticarial vasculitic syndrome. 13 Schnabel et al 14 reported an increased incidence of hemosiderin-laden macrophages in patients with ANCA-associated vasculitis and pulmonary disease compared with patients with CTD-associated interstitial lung disease. Patients with increased iron-positive macrophages had higher disease activity, a higher ANCA titer, a higher myeloperoxidase (MPO) concentration in the BAL fluid, and more frequent low-attenuation opacities on HRCT compared with patients with a low iron-positive cell count. Furthermore, idiopathic pulmonary hemosiderosis is characterized by diffuse alveolar hemorrhage with hemosiderin-laden macrophages, restrictive lung disease, and interstitial fibrosis. 15, 16 The second hypothesis that may explain lung fibrosis is that MPO-ANCAs play a direct role in the pathogenesis of PF. The constant positivity of anti-MPO antibodies in the reported case series and animal models 17 suggests a putative role for MPO-ANCAs in the pathogenesis of PF. ANCA antigens such as MPO undergo translocation to the surface of neutrophils (possibly in response to proinflammatory cytokines), and subsequent binding of circulating ANCAs results in neutrophil degranulation and the release of reactive oxygen species, causing injury and consequent fibrosis. [17] [18] [19] This hypothesis is further supported by the findings that in patients with rheumatoid arthritis (RA), ANCA positivity, essentially anti-MPO, was associated with more active disease, occurrence of vasculitis, and more extraarticular manifestations, including PF. 20, 21 Therapy Data regarding therapy are limited to small retrospective studies with heterogeneous populations. Optimal therapy is controversial. A prospective multicenter trial for patients with newly diagnosed MPO-ANCA-associated vasculitis (J [Japanese] MAAV) was performed to evaluate the impact or immunosuppression therapy for remission induction (manuscript submitted).
Among 48 patients with MPO-ANCA-associated vasculitis, PF was identified in 22 patients (46%) at the diagnosis of vasculitis. Concomitant organ involvement included renal involvement in 15/22 (68%), peripheral neuropathy in two (9%), pulmonary-muscle syndrome in two (9%), and no extrapulmonary involvement in three (14%). Chest HRCT was performed in 21 patients before remission-induction therapy. Lung fibrosis was found in 18 patients (86%). The most prevalent HRCT findings included honeycombing (52%), GGOs (48%), emphysema (38%), and consolidation (29%). It was notable that lung fibrosis of eight patients with emphysema corresponded to the recently proposed syndrome ''combined PF and emphysema (CPFE).'' 22 Following induction therapy, vital capacity improved >10% in approximately half of patients with PF, particularly when cyclophosphamide was included in the treatment regimen (manuscript in preparation). By contrast, in their cohort of 12 patients with ANCA-associated PF, none of 12 patients improved with immunosuppressive therapy. Furthermore, ANCA titers did not correlate with the course of vasculitis or evolution of fibrosis. 6 The mechanisms responsible for lung fibrosis, ANCA production, and vasculitis may be multifactorial and interactive. The role of cofactors such as genetic background and environmental factors (particularly tobacco smoking) has not been elucidated. International prospective long-term studies are required to better define the pathogenesis of ANCA-associated lung fibrosis and facilitate development of effective therapy.
